Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,974 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT07697937RecruitingPhase 2
YH02 injection for advanced solid tumors that didn't respond to treatment
This trial tests a new injection, YH02, directly into tumors for people with advanced solid tumors (like head and neck, breast, or melanoma) that are no longer responding to standard treatments. The goal is to see if it can shrink tumors or slow disease progression.
TianjinAges 18 years+ - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04965077RecruitingPhase 1
First study of MIL97 for advanced solid tumors
This Phase 1 trial tests MIL97, a new treatment, in adults with advanced solid cancers that have come back or cannot be removed. The goal is to find a safe dose and see how the cancer responds.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT04984551RecruitingPhase 2
Training plus support to improve palliative care for advanced cancer
This trial studies whether a program called Project ECHO can improve the quality of palliative care (comfort-focused care) for people with advanced cancer and their caregivers in underserved areas. It also involves training local health care providers so they can better support patients and families over time.
Houston, TexasAges Any age - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05099809Recruiting
Hyperthermia plus treatment for locally advanced cancers
This registry study looks at whether adding hyperthermia (raising body temperature) is safe and effective for people with certain locally advanced, non-spread cancers. It will follow outcomes to help doctors understand who may benefit and what side effects to expect.
Sevāgrām, MaharashtraAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT05112991RecruitingPhase 2
Check whether envafolimab plus lenvatinib helps advanced uterine cancer
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Orange, CaliforniaAges 12 years+ - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT05156060RecruitingPhase 1/Phase 2
Gabapentin and ketamine to treat head and neck cancer pain
This early-phase study tests whether gabapentin and a ketamine nasal spray can help prevent or lessen short-term and long-term pain from locally advanced head and neck cancer. It may help by changing how the nervous system responds to pain during and after radiation and chemoradiation.
Nashville, TennesseeAges 21 years+ - NCT05156203RecruitingPhase 1
T-1301 capsules test for advanced solid tumor cancers
This early-phase study tests whether T-1301 capsules are safe and how well they can work in people with advanced solid tumors that can’t be treated with standard options. It focuses on side effects first, but results may help guide future treatment for advanced cancers.
Kaohsiung CityAges 20 years+ - NCT05166694Recruiting
Personalized testing to check drug interactions and gene effects
This study uses personalized information to help understand how your current medicines interact with each other and with your genes. It may help your care team choose safer, more effective medication plans for you.
Chicago, IllinoisAges 18 years+ - NCT05177055Recruiting
Sleep program for delayed sleep timing with mental health symptoms
This study offers a sleep-focused program to people whose sleep schedule is significantly shifted later than desired (delayed sleep phase disorder) along with moderate to severe mental health symptoms. It aims to see if treatment for the sleep problem can help in people already getting psychiatric care.
Bergen, TertnesAges 18–80
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,974 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.